Over 50 new vaccine options have launched in less than a decade — an unprecedented opportunity for governments to optimise routine immunisation:
✅ higher coverage
✅ reduced costs
✅ better cold chain use
✅ stronger supply security
Despite this progress, uptake remains difficult to predict—especially for innovations made in the Global South. To plan for sustainable supply and affordable prices, we need to understand what drives (and blocks) countries’ vaccine choices. University of Geneva‘s Center for Vaccinology have launched a global study and invite immunization decision-makers and advisors in middle, lower-middle and low-income countries to take part in this survey which will close on 20 October 2025. The survey is available in six languages: English, Arabic, French, Russian, Spanish and Portuguese. You can find the survey invite in non-English languages below.
By participating, you’ll help:
Findings will be openly shared through public platforms and peer-reviewed publications—contributing to collective insight for impact in global health.
With thanks to Centre for Behavioural and Implementation Science Interventions (BISI) for the research collaboration, along with partners from NITAG Support Hub (NISH), UNICEF, World Health Organization, Every Breath Counts Coalition, Clinton Health Access Initiative, Inc., Murdoch Children’s Research Institute (MCRI), Gavi, the Vaccine Alliance, JSI, Ipsos in the UK.
This study is led from the University of Geneva and received ethical clearance from the Committee for ethical research. It is funded by Gates Foundation.
